Athenex To Start US Trial Of Oral Docetaxel Product

Athenex, a US-China cancer company, received FDA permission to start US clinical trials of its oral formulation of the chemotherapy docetaxel. Athenex developed Oradoxel using P-glycoprotein (Pgp) pump inhibitor technology that it in-licensed from South Korea's Hanmi Pharma. Oradoxel is the third clinical program developed from the Pgp technology and the company's sixth cancer drug approved for US clinical trials. In October 2015, Athenex struck a deal with Chongqing, China to build two manufacturing plants there. Athenex has also established a joint lab with Hong Kong Polytechnic University, which did much of the work on Oradoxel.